Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Enanta Pharmaceutica
(NQ:
ENTA
)
11.57
-1.04 (-8.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Enanta Pharmaceutica
< Previous
1
2
3
4
5
6
7
Next >
Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023
May 02, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million
April 25, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
April 17, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Expert Ratings for Enanta Pharma
March 22, 2023
Via
Benzinga
Enanta Pharmaceuticals's Earnings: A Preview
February 06, 2023
Via
Benzinga
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
April 06, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
April 05, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
March 14, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Earnings Outlook For Enanta Pharmaceuticals
November 18, 2022
Via
Benzinga
Recap: Enanta Pharmaceuticals Q3 Earnings
August 08, 2022
Enanta Pharmaceuticals (NASDAQ:ENTA) reported its Q3 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
10 Companies That Had Tons of Money in SVB When It Collapsed
March 13, 2023
Silicon Valley Bank is gone but its clients are still here. Many prominent companies, and not just startups, had money in SVB.
Via
InvestorPlace
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
March 08, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 07, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET
February 07, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
February 07, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022
January 31, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference
January 06, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Participate in Two Investor Conferences in November
November 22, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
November 21, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Earnings Scheduled For November 21, 2022
November 21, 2022
Companies Reporting Before The Bell • Zepp Health (NYSE:ZEPP) is expected to report quarterly earnings at $0.54 per share on revenue of $186.58 million.
Via
Benzinga
Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022
November 14, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19
November 09, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022
October 19, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus
October 17, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus
October 03, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium
September 29, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium
September 22, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
New Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022
September 07, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Participate in Two Investor Conferences in September
September 01, 2022
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.